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Abstract: The long-term sequelae of coronavirus disease 2019 (COVID-19) are only now beginning to
be defined, but it is already known that the disease can have direct and indirect impacts mainly on the
cardiorespiratory and neuromuscular systems and may affect mental health. A role for rehabilitation
professionals from all disciplines in addressing COVID-19 sequelae is recognised, but it is essential
that patient assessment be systematic if health complications are to be identified and treated and,
if possible, prevented. The aim is to present a COVID-19 prospective surveillance model based
on sensitive and easily used assessment tools, which is urgently required. Following the Oxford
Centre for Evidence-Based Medicine Level of Evidence Tool, an expert team in cardiorespiratory,
neuromuscular and mental health worked via telemeetings to establish a model that provides
guidelines to rehabilitation professionals working with patients who require rehabilitation after
suffering from COVID-19. A COVID-19 prospective surveillance model is proposed for use by
rehabilitation professionals and includes both face-to-face and telematic monitoring components. This
model should facilitate the early identification and management of long-term COVID-19 sequelae,
thus responding to an arising need.
Keywords: cardiorespiratory system; COVID-19; mental health; neuromuscular system; prospective
surveillance model
1. Introduction
Multisystem long-term sequelae are being described following severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection, with a high impact at cardiorespiratory,
neuromuscular [1] and psychological levels [1,2] and possibly other systems [3]. The latest
reports have established that 26% of patients needed hospitalisation, and among them,
14% required an intensive care unit (ICU) admission and/or respiratory support [4]. The
long-term sequelae of the infection are now beginning to be defined; many may seriously
impair the health of individuals and have important knock-on economic effects [5]. Given
the similarities between coronavirus disease 2019 (COVID-19) and diseases caused by other
coronaviruses [6], post-acute and long-term sequelae that require specific treatment should
be expected [1,7]. The number of people eventually requiring attention for COVID-19
sequelae could be high: on 30 January 2021, the present pandemic had already affected
102,107,858 people worldwide [8], being the main worldwide health problem with an
uncertain future.
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Recent data show that individuals with a severe presentation of the illness have
underlying comorbidities such as hypertension, diabetes, cardiovascular disease (CVD)
or cerebrovascular disease [9], and hospitalised patients require a long hospital (around
4–53 days) or ICU (4–19 days) stay [10]. In addition, it must be considered that these
patients may suffer from the iatrogenic effects of COVID-19 treatment [11] (Figure 1).
Together, these factors render them vulnerable to loss of function and reduced quality of
life after release from the hospital [6]. Most of these health issues can be at least partly
treated by rehabilitation professionals (RPs) from all disciplines. Indeed, a role for the RP
in addressing these sequelae is recognised [12,13], but it is essential that patient assessment
be systematic if further health complications are to be identified, treated and, if possible,
prevented. Clear guidelines are therefore required (1) to help RPs evaluate the likelihood
of a patient experiencing major health deterioration and (2) assist them in providing
appropriate treatment. Some previous studies [14,15] have presented successful models for
assistance in early detection of health-related issues and the ability to take fast actions. In
ICU-admitted patients, a real-time surveillance model was used to predict acute respiratory
distress syndrome (ARDS) prior to its onset, with multiple, non-invasive and easy-to-collect
vital signs, related to the risk factors that associate with ARDS, and easy to translate to
home surveillance. This model was found to outperform the classical tests [14]. Another
example in ICU-admitted patients is a model that successfully predicted ARDS events
to support early diagnosis and intervention to improve survival rates [15]. In patients
with cancer, several similar prospective surveillance models (PSMs) for physiotherapy
interventions have been developed [16–19]. These previous experiences led us to suggest
that the implementation of this COVID-19 PSM would be feasible [18], may identify
early impairment [18–20], predict the severity of possible impairments [16,17], allow early
intervention [19,21,22] and potentially save resources [22].
Figure 1. Profile of patients likely to require rehabilitation after coronavirus disease 2019 (COVID-19).
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Currently, to the best of our knowledge, there are four models for COVID-19 [23–25].
These models successfully aim to optimise resource expenses in preoperative tests, while
considering personal safety [23]; preserve resources of ambulatory service [24]; predict
high-risk patients with admission data [25]; and a multidisciplinary model that aimed
to detect patients with increased physical and mental health care needs [26]. However,
considering the possible long-term sequelae of COVID-19 [27] and long-COVID-19 with
persistent symptoms [28,29], we have not found any model that focusses on monitoring
these impairments, with follow-up periods, after COVID-19 and focusses on impairments
approachable from physiotherapy. Therefore, considering previous models, we propose a
PSM for early detection that allows early intervention by physiotherapists with the aim to
improve current health assistance.
The present work proposes a prospective surveillance model (PSM), based on sensitive
and easily used assessment tools, for use by RPs when treating patients who require
rehabilitation after suffering from COVID-19. Importantly, this PSM contemplates face-to-
face and telematic patient monitoring.
2. Methodology
A panel of RPs (I.C.-V., M.A.-M., J.S.-C., A.L.-P., E.C.-M. and P.P.-M.), the members of
which are experts in alterations of functionality (I.C.-V., M.A.-M. and J.S.-C.), the cardiores-
piratory system (M.A.-M. and A.L.-P.), the neuromuscular system (E.C.-M.) and mental
health (E.C.-M. and P.P.-M.), was brought together to prepare the proposed COVID-19
prospective surveillance model (COVID19-PSM). The process began at the end of March
after detecting the urgent need to offer RP support beyond acute care for the disease. After
initial contact, it was decided that the Oxford Centre for Evidence-Based Medicine Level
of Evidence Tool [30] will be used to establish decision-making. After the selection of
panel members (performed by I.C.-V. and M.A.-M.), the following tasks were undertaken
by those with the corresponding expertise: (1) a review of the epidemiological literature
(P.P.-M.) and (2) a review of the available information regarding the involvement of, and
the sequelae affecting, the cardiovascular (I.C.-V. and M.A.-M.), respiratory (A.L.-P.), neuro-
logical (E.C.-M.) and musculoskeletal (I.C.-V., M.A.-M. and J.S.-C.) systems, as well as the
mental health problems associated with COVID-19 (E.C.-M.). The latter reviews included
the clinical assessment tools available for identifying risk thresholds and treatment options.
Information was also sought about the main components of PSMs (Table 1). These tasks
involved searches of Medline (PubMed), the Web of Science, Medrxiv and official resources
(e.g., documents published by the World Health Organisation -WHO- and the Centers for
Disease Control and Prevention -CDC-). Search terms were modified to fit each database.
No language restriction was enforced.
Table 1. Search strategy used with PubMed (later adapted for use with the other databases searched).
Condition
1 (COVID-19 [tiab]) OR (Coronavirus disease 2019[tiab]) OR (COVID *[tiab])
Cardiopulmonary system
2
(exercise[Mesh]) OR (physical activity [tiab]) OR (physical exercise[tiab]) OR
(cardiovascular system[Mesh]) OR (cardiovascular systems[tiab]) OR (circulatory
system[tiab]) or (circulatory systems[tiab]) OR (cardiorespiratory fitness [Mesh]) OR
(cardiorespiratory exercise testing [tiab]) OR (functional capacity [tiab]) OR (respiratory
system[Mesh]) OR (respiratory systems[tiab]) OR (respiratory tract[tiab]) OR (respiratory




(musculoskeletal system[Mesh]) OR (musculoskeletal systems[tiab]) OR (nervous
system[Mesh]) OR (neuralgia [Mesh]) OR (neuropathic pain[tiab]) OR (neuropathies[tiab])
OR (myalgia[tiab]) OR (paresthesia[Mesh]) OR (neurologic manifestation[Mesh])




4 (mental health [Mesh terms]) OR (mental hygiene[tiab]).
Definitive search
5 1 AND 2
6 1 AND 3
7 1 AND 4
Each expert assessed the quality of the information available in their field using the
Oxford Centre for Evidence-Based Medicine (OCEBM) 2009 Level of Evidence Tool (see
Supplementary Materials S1) and sent a final report to the lead author (I.C.-V.). These
reports were then organised into a single document, which was distributed to all panel
members for comprehensive study. Telemeetings were then held to discuss the desirability
of including the collected information in the proposed PSM. Decisions were taken by
voting; ≥70% consensus was required for all inclusion/exclusion decisions. In total, three
telemeetings (held between March 30th and 15th June 2020) were needed to define the
contents of the PSM.
3. The Proposed Prospective Surveillance Model
The proposed COVID19-PSM for use by RPs (Figure 2) is divided into three sections:
rapid screening, general assessment and specific assessments for each system likely to be
affected. The latter section includes reliable tools for making necessary assessments, cut-off
points and orientation regarding treatment.
3.1. Rapid Screening
The possibility that a patient has been re-infected with SARS-CoV-2 needs to be quickly
ruled out. This can be done via the screening questions [31] shown in Figure 2. Re-infection
is a red flag that demands immediate referral to a specialist; patients with active COVID-19
should not be treated using the proposed PSM as a guide.
Once re-infection has been ruled out, anamnesis can be performed to detect further
red flags [32] and grey flags regarding sequelae. The term grey flag is here proposed to
describe findings that need to be borne in mind by the RP, since they may complicate
recovery and accelerate the possibility of a process becoming chronic, but that do not
require immediate referral to a specialist. Such grey flags may reflect factors related to
comorbidities, the treatment received for COVID-19 and biopsychosocial and work-related
matters. Anamnesis can be performed by phone or via the internet [7] and should be
whenever possible.
3.2. General Assessment
This includes a number of simple assessments to detect health concerns that should
indicate any condition that might be driving the emergence or perpetuation of more serious
health issues (Figure 2). The results provide information regarding the need for more spe-
cific assessments and help in the design of intervention strategies. It should be remembered
that COVID-19 commonly affects persons with a sedentary lifestyle and reduced physical
activity [33], who are usually overweight and/or who have hypertension, cardiovascular
disease and/or diabetes [9]. It may well be that after suffering from COVID-19, patients
move even less than before [34]. This can facilitate the appearance of comorbidities or
accentuate those already present [35]. RPs should therefore encourage salutogenesis in
their patients [36]. Online technologies, which have already been used in other health
settings for this purpose [7], might be adapted for use with survivors of COVID-19.
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Figure 2. The proposed COVID-19 prospective surveillance model for use by physiotherapists. ADLs:
activities of daily living; BP: blood pressure; BT: body temperature; CPET: cardiopulmonary exercise
testing; CSI: central sensitization inventory; FEV1: forced expiratory volume; FVC: forced vital
capacity; GMI: graded motor imagery; HADS: hospital anxiety and depression scale; HR: heart rate;
ICU: intensive care unit; ICUAP: ICU-acquired paresis; IES-R: Impact of events scale-revised; IPAQ:
international physical activity questionnaire; LANSS: Leeds Assessment of Neuropathic Symptoms
and Signs; MEP: maximum expiratory pressure; MIP: maximal inspiratory pressure; mMRC: modified
medical research council; MoCA: Montreal cognitive assessment; MRC: Medical Research Council
Scale; PTSD: post-traumatic stress disorder; QoL: quality of life; RR: respiratory rate; SF-36; The
Short Form-36 Health Survey; SpO2: peripheral capillary oxygen saturation; SPPB: short physical
performance battery; VAS: visual analogue scale; VC: vital capacity; Vo2peak: peak rate of oxygen
uptake; 6MWT: 6 minute walking test; *: refer to specialist.
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3.3. Specific Assessments
3.3.1. Cardiorespiratory System
Based on the effects of severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS) [6], both caused by coronaviruses, long-term cardiac and
pulmonary sequelae might be expected to develop after suffering from COVID-19 [37].
Indeed, some 32.8–70% of patients hospitalised because of COVID-19 develop ARDS [38],
and some 20% of these are known to suffer cardiac sequelae [39]. For instance, having
a history of stroke increases the risk of death from COVID-19 by up to three times [40],
and out of those patients with a severe presentation, 5.7% developed cerebrovascular
complications [41]. It has also been described that following post-intensive care syndrome
(PICS), patients may show reduced pulmonary function, weakness of the respiratory
muscles [32] and cardiovascular complications (e.g., myocardial injury) [42] that might
persist for months and possibly even years. Thus, specific cardiorespiratory assessments
(Figure 2) should be made frequently, and the patient referred to a specialist if there is any
suspicion of an abnormality (e.g., an altered spirometry pattern, hypertension, high resting
heart rate, thrombotic events, etc.).
3.3.2. Neuromuscular System
Around 20% [43] of patients who develop severe or critical clinical COVID-19 are at
risk of neuromuscular complications [44], such as critical illness polyneuropathy or critical
illness myopathy (CIP or CIM, respectively). Certainly, 25–68% of patients with ARDS who
have been admitted to an intensive care unit for a long period develop CIP or CIM [45].
The same might therefore be expected in patients with severe COVID-19 who may also
spend a long time in intensive care [38]. Neurological sequelae have also been described for
both SARS and MERS [46,47]. These complications affect the patients’ general functional
capacity, making it difficult for those affected to perform normal activities of daily living
or to return to work [32] (which entails economic problems). The proposed COVID19-
PSM includes common quantitative tests for muscle weakness, functional capacity, joint
mobility, balance, polyneuropathy, neuralgia and neuropathic pain able to identify possible
long-term sequelae (Figure 2). The systematisation of these assessments should allow for
early identification and appropriate intervention and help decide on the need for referral
to other health professionals.
3.3.3. Mental Health
Mental health can be compromised in survivors of ARDS [48] and PICS [32]. For
example, at discharge from intensive care, 70–100% of patients with ARDS may show
cognitive decline [49], which may be long term. Indeed, 46–80% of these patients remain
affected at one year and 30% at five years [49]. It is already becoming clear that COVID-19
survivors who required intensive care are at risk of such long-term problems [2], but they
may also suffer depression, anxiety and post-traumatic stress disorder [32]. These condi-
tions are believed to compromise the immune system and may complicate recovery [50].
This COVID19-PSM therefore includes mental health assessments to detect a range of
problems (Figure 2). Patients identified as suffering from mental health problems should
be referred to an appropriate specialist.
4. Discussion
This study presents a PSM for the early detection of long-term COVID-19 sequelae
to adopt preventive strategies and propose treatment measures. In physiotherapy, there
are not many studies that have addressed problems this way, although there are some
important PSMs in a population such as cancer. Regarding diagnosis and prevention, the
implementation of these previous models has allowed researchers to detect early impair-
ments or their severity and make an early intervention [16–19]. The same occurs in our
PSM, which aims to address COVID-19 or long-COVID-19 sequelae and side effects derived
from its management in the ICU and benefits from an early stage and suggest intervention.
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In addition, there is already a model in COVID-19 [26] that detects patients with increased
physical and mental health care needs. However, that model is multidisciplinary, and
the one we presented is centred in physiotherapy as there are many COVID-19-related
sequelae that physiotherapists can manage. Regarding cost-effectiveness, previous models
have been shown to potentially save resources [19], yet we do not know whether our PSM
will be cost-effective, and if effective, it will save the costs derived from impairments in a
long-term period by avoiding them from the earliest moment.
The key point of this PSM is the suggestion of the use of affordable instruments capable
of detecting early impairments on the main systems affected by COVID-19: (1) at the first
evaluation, with rapid screening through exploratory questions; (2) at general health
assessment (vital signs, auscultation, dyspnoea, body composition, physical activity level,
sedentary lifestyle and quality of life); and (3) at specific evaluation of cardiorespiratory,
neuromuscular and mental levels (Figure 2). It should be noted that the PSM allows the
detection of health problems that require referral to specialists (marked with an asterisk
in Figure 2); it being a disease that affects multiple systems, with varying degrees of
involvement, management with multidisciplinary groups is the optimal decision.
The questions that appear in the rapid screening (Figure 2, Number 1) have been
used for the detection of PICS [32] and musculoskeletal disorder [51] complications in
adults, and its inclusion within the evaluation and treatment processes has shown to
improve outcomes in physiotherapy units [52]. Currently, there is a fundamental question
oriented to detect a person with an active COVID-19 illness (Did you have symptoms of
COVID-19 recently?), our red flag, that must precede any assessment [31]. After this, the
following proposed questions try to deepen the situation experienced by each patient; they
should be considered as they can influence correct rehabilitation, but they do not require
immediate referral.
The general assessment (Figure 2, Number 2) aims to have an overall picture of the
health status of patients, for which it establishes cut-off points stated for COVID-19 [53],
international guidelines [53,54] or validation studies [55]. These cut-off points serve for
identifying potential health risks before starting rehabilitation and should be considered
as exclusion criteria for safety. These gather values of blood pressure (BP) of <90/60
or >140/90 mmHg, a heart rate (HR) of >100 beats/min, peripheral capillary oxygen
saturation (SpO2) of <95% [53], a respiratory rate (RR) of <12 or >20 bpm [55], a body
temperature (BT) of >37.2 ◦C or dyspnoea of ≥2 grade in the modified Medical Research
Council (mMRC) scale [54].
Another parameter to consider is the waist circumference, which is becoming more
important and even has been considered by some authors as a vital sign [56] due to its
important relationship with morbidity [57] and cardiovascular death [58]. Regarding
this, the WHO established values of ≥90 cm in women and ≥100 cm in men as cut-off
points of higher risks for heart disease, diabetes and stroke [59]. Waist circumference is a
surrogate measure of visceral fat [60] that has been linked to being present in patients with
higher COVID-19 severity [61] and a stronger need for intensive care [62], who usually
are more physically inactive [63] and sedentary [64], and these numbers have risen during
the pandemic [65], favouring, therefore, weight gain [66]. This can be easily assessed [67].
In fact, already up to 47.7% of the worldwide population [68] and up to 72% in Europe
were physically inactive and 23% were sedentary (with >10 h sitting per day). In addition,
it was calculated that 9% were both physically inactive and sedentary [69]. Moreover,
emerging evidence during the pandemic is showing that maintaining physical exercise
practice outwards or inwards decreases COVID-19 severity [70]. Recommended levels
of physical activity [71] and cut-off points [67,72] during the pandemic are only for the
general population, but it is proposed that COVID-19 survivors regain physical activity
with a safe stratify strategy [73]. A study stated that young and middle-aged adults who
are moderately and/or severely affected usually have hypertension and overweight and
suffer a significant impact on their quality of life [26]. It is therefore important to include
a quality-of-life assessment [74] to check patients’ perception of their own physical and
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psychological well-being [75], which is already known to suffer from a reduction in all
spheres [76].
To perform a specific evaluation (Figure 2,), it is important to follow a hierarchy
in system impairments, going through health indicators with solid scientific evidence,
which may be transferable to COVID-19 or long-COVID-19 survivors. It is important
to measure the integrity of cardiopulmonary function, whose importance has increased
due to COVID-19’s effects on this system, with impairments of 26% mid-term [76] to 46%
long-term COVID-19 sequelae [77]. A recent study [76] showed a reduction in the maximal
oxygen consumption and in the walked distance in the 6 min walking test (6MWT) after
2–3 months of moderate–severe COVID-19. Impairment has been considered in other
population as values of peak oxygen consumption (VO2peak) of ≤15 mL/kg/min with
a cardiopulmonary exercise test (CPET) [78], or <350 m with the 6MWT [79], or a gait
speed <1m/s (REF). The CPET should be performed in situations of medical control,
with exhaustive monitoring [80–82], considered the gold standard [83], and allows the
detection of problems that should be assessed by a specialist. Although it could be too
demanding, the 6MWT is an optimal alternative to use, both the CPET and 6MWT are
already used in COVID-19 patients [84,85]. When an impairment is found, cardiovascular
exercise of moderate intensity [32], with control of SpO2 (to stop if values decrease by
<90% or a decrease by more than 4% from baseline [86]) and rate of perceived exertion in
the Borg scale between 3 and 5 [87], is recommended for optimal outcome and safety [32].
Another parameter of interest is the recovery HR, which reflects the reactivation of the
parasympathetic system after physical exercise, and it is implicated in cardiovascular risk
events and all-cause mortality [88]. Monitoring objective fitness data is helpful to control
the exercise tolerance in COVID-19 patients [73]. These data have been found deficient if
the difference from the maximal achieved during physical exercise [89] is <10 or <20 after
one and two minutes, respectively [88]. We believe that this indicator should be included
as it is a simple and affordable measure to check cardiovascular issues related to exercise
tolerance [88].
Long-term pulmonary impairments are present in up to 29% of COVID-19 sur-
vivors [27]. The key parameters regarding lung function are forced spirometry and simple
spirometry as they have been set as the main methods to perform a respiratory function
assessment [90]. The parameters to be considered as abnormal functions are forced vital
capacity (FVC) and forced expiratory volume (FEV1) of <80% and FEV1/FVC of <0.7 [90].
These assessments should be complemented by respiratory muscle assessment with maxi-
mal inspiratory pressure (MIP) and maximum expiratory pressure (MEP) as the specific
outcomes [91], where values of <65–80% for the MIP or MEP are considered pathological
values [92]. Respiratory physiotherapy plays a crucial role in COVID-19 rehabilitation [93],
and there are very specific techniques from Physiotherapy such as pulmonary rehabilita-
tion [37,94] and respiratory muscle training [95], with evidence that they are useful in the
management of this situation. It is recommended that physiotherapists consider a referral
to specialists if important impairments are found.
A wide variety of affectations at a neuromuscular level have been described in COVID-
19 survivors, such as facial paresis, Guillain-Barré syndrome, neuropathies, CIP and CIM,
myalgia and myositis, among others [96], affecting functional capacity and activities of
daily living [32]. For that reason, it is important to assess all parameters that help in
detecting major problems [38,44,46]. In particular, due to the prolonged rest situation,
muscle weakness, ambulation and balance must be assessed. These assessments are
muscle weakness with grip strength (with cut-off points of dysfunction of <25.8 [97] and
<11 kg [97] in men and <17.4 [98] and <7 kg [98] in women, being the last measure from ICU-
acquired paresis) and the MRC scale of ≤48 points [99]. The activities of daily living might
be affected as a consequence [32,47], so an assessment with the Barthel Index should be
performed [100]. In addition, functional capacity should be assessed with the timed-up-and-
go cut-off point of >20 s [101] and the short physical performance battery of <10 points [102],
joint mobility with a goniometry assessment [103] and balance with the Berg Balance Scale
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and a cut-off of <49 points [104]. For polyneuropathy, neuralgia and neuropathic pain, a cut-
off of ≥12 points is suggested in the Leeds Assessment of Neuropathic Symptoms and Signs
(LANSS) scale [105]; the updated grading system and the grading of possible, probable or
definite result [106]; and a visual analogue scale (VAS) of 4–6 as moderate or ≥7 as severe
pain [107]. For these alterations, a multimodal therapeutic exercise [108] programme that
includes aerobic, strength, stretching and balance has already been effective [109]. In fact,
an aerobic programme has already been recommended [110], and strength programmes are
already being implemented to assess muscle weakness in COVID-19 survivors [111]. For
polyneuropathy, neuralgia and neuropathic pain, an intervention of electrotherapy [112],
therapeutic exercise, virtual reality and graded motor imagery (GMI) [113] is also suggested,
which has been effective in other populations, as there is little information about most
neuromuscular alterations in COVID-19 survivors [114].
That these alterations may facilitate or be related to chronic pain [114] or an underlying
central sensitisation must be considered as well [115]. For efficient detection of central
sensitisation, the use of the central sensitisation inventory (CSI) has been recommended,
where values of >40 or >50 points indicate moderate or severe central sensitisation based
on comorbid symptoms and conditions of other central sensitisation syndromes [116]. For
this purpose, physiotherapy has many techniques to include in the intervention, such as
manual therapy (neural mobilisation, low-velocity mobilisation and high-velocity mobili-
sation) [117], multimodal therapeutic exercise [32], neuroscience education [117], motor
imagery and cognition-targeted exercise therapy [118] used in patients with nociceptive or
chronic pain. Moreover, chronic pain and central sensitisation form a close cluster, together
with anxiety and depression [119]; therefore, they also must be addressed. Some studies
have shown the prevalence of psychopathology and psychiatric sequelae in COVID-19 sur-
vivors, finding a presentation of 42% for anxiety, 31% for depression, 28% for post-traumatic
stress disorder and 20% for obsessive-compulsive symptoms 1 month after hospital ad-
mission [120]. There are few data in a long-term period, but there have been findings of
cognitive impairment 3 months post-discharge [121], so they may be present later as well if
not addressed, as has happened in other coronavirus outbreaks with months to years of
impairment [122]. From the perspective of physiotherapy, it is important to address and
consider these alterations in our intervention. However, facing a well-established alteration
involving depression, anxiety, post-traumatic stress disorder and cognitive impairments, a
cut-off of ≥8 points in the Hospital Anxiety and Depression Scale (HADS) [123], ≥1.6 on
the Impact of Events Scale—Revised [124] and/or >18 points on the Montreal Cognitive
Assessment (MoCA) scale [125], respectively, has been proposed to consider a referral to
a specialist.
Limitations, Key Findings, and Future Directions
This PSM model has some limitations. It uses several cut-off points that have not
been validated in COVID-19 survivors but can be transferable. Neither has the PSM model
been validated yet. However, we present a hierarchical model with a potential for easy
implementation and benefits in primary, secondary and tertiary prevention.
COVID-19 will be with us longer than expected, with consequences not yet well
established and affecting the whole population [126]. The number of COVID-19 survivors
will continue to grow, leading to an increasing number of people with health needs [28,127],
and it will be common to find people with different related problems. Implementing this
PSM could be the start to protocolise research in the area of physiotherapy and COVID-19.
In future research, the feasibility, effectiveness and cost-effectiveness of this PSM could
be explored.
5. Conclusions
In summary, the proposed COVID19-PSM should facilitate early identification and
management of long-term COVID-19 sequelae, thus responding to an arising need [6].
Work is now needed to demonstrate the reliability and cost-effectiveness of this PSM.
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